大麻二酚与氯巴占相互作用的临床试验模拟及对跌倒发作频率的影响
本研究通过临床试验模拟检验假设:大麻二酚对Lennox-Gastaut综合征和Dravet综合征患者跌倒发作频率的效应可能归因于与氯巴占的药物相互作用。模拟假设服用10或20 mg氯巴占的患者N-去甲氯巴占暴露增加2至7倍,而未服用氯巴占者的跌倒发作频率中位降低及降低百分比变异与安慰剂组相似。结果显示大麻二酚对Lennox-Gastaut综合征患者跌倒发作频率中位降低的效应可能由与氯巴占的药物相互作用解释,这对大麻二酚的使用及其FDA注册可能有重要意义。
要点
- 大麻二酚对跌倒发作的疗效可能部分由与氯巴占的相互作用介导。
- 服用氯巴占者N-去甲氯巴占暴露增加2至7倍。
- 未服氯巴占者的发作频率降低与安慰剂组相似。
核心结论
- 大麻二酚对Lennox-Gastaut综合征患者跌倒发作频率的中位降低效应可能由与氯巴占的药物相互作用解释。
研究设计与样本
- 临床试验模拟研究,模拟20 mg/kg/天大麻二酚对Lennox-Gastaut综合征患者跌倒发作频率的效应。
主要发现
- 假设服用10或20 mg氯巴占的患者N-去甲氯巴占暴露增加2至7倍。
- 假设未服用氯巴占的患者跌倒发作频率中位降低及降低百分比变异与安慰剂组相似。
- 模拟结果显示大麻二酚对跌倒发作频率的中位降低效应可能由与氯巴占的相互作用解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With this study, we aim to test the hypothesis that the effect of cannabidiol on drop-seizure frequency in patients with Lennox-Gastaut syndrome and Dravet syndrome could be attributed to a drug-drug interaction with clobazam. We performed clinical trial simulations for the effect of 20 mg/kg/day cannabidiol on drop-seizure frequency in patients with Lennox-Gastaut syndrome. We assumed that patients taking 10 or 20 mg clobazam would have a 2- to 7-fold increase in N-desmethylclobazam exposure, whereas patients not taking clobazam would have a median reduction in drop-seizure frequency and a variability in the percent reduction similar to the placebo group. The results show that the effect of cannabidiol on the median reduction in drop-seizure frequency in patients with Lennox-Gastaut syndrome may be explained by a drug-drug interaction with clobazam. This may have important implications for the use of cannabidiol and its Food and Drug Administration registration.
引用
- Bergmann KR, Broekhuizen K, Groeneveld GJ, et al. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency. Br J Clin Pharmacol. 2019. PMID: 31657863. doi:10.1111/bcp.14158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。